Actively Recruiting
Evaluation of PUMCH-E111 Eye Injection for Safety and Effectiveness in Adults with RLBP1-Related Inherited Retinal Dystrophy
Led by Peking Union Medical College Hospital · Updated on 2026-06-18
6
Participants Needed
1
Research Sites
204 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effectiveness of PUMCH-E111 injection in adults with RLBP1-related Inherited Retinal Dystrophy IRD, a genetic eye condition. This early phase 1 trial aims to understand how this treatment works for this specific form of inherited retinal disease. Participants will receive a single intravitreal injection of PUMCH-E111 in one eye. The study includes two dose levelsa low dose and a high dosein separate groups. After the injection, participants will be followed closely for 52 weeks, with ongoing monitoring continuing for up to 5 years after enrollment to assess long-term effects. During the study, participants will undergo various tests to monitor safety and visual function. Researchers will track any dose-limiting toxicities within the first 4 weeks and adverse events up to 52 weeks. Visual function will be assessed regularly to understand the treatments impact. Safety and health monitoring will continue throughout the extended follow-up period, ensuring ongoing evaluation of the treatments effects and participant well-being.
CONDITIONS
Brief Title
Safety and Efficacy Study of PUMCH-E111 Injection in Subjects With RLBP1 Related Inherited Retinal Dystrophy
Research Team
R
Ruifang Sui, MD, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here